Literature DB >> 23764959

Serum osteopontin concentration is decreased by exercise-induced fat loss but is not correlated with body fat percentage in obese humans.

Jeong Soon You1, Hye-In Ji, Kyung Ja Chang, Myung Chul Yoo, Hyung-In Yang, In-Kyung Jeong, Kyoung Soo Kim.   

Abstract

To evaluate the extent to which fat mass contributes to serum osteopontin (OPN) concentration, we investigated whether serum OPN levels are decreased by exercise-induced fat mass loss and whether they are associated with body fat percentage in obese humans. Twenty‑three female college students were recruited to participate in an 8‑week body weight control program. Body composition [body weight, soft lean mass, body fat mass, body fat percentage, waist-hip ratio and body mass index (BMI)] were assessed prior to and following the program. Serum lipid profiles and serum adiponectin, leptin and osteopontin levels were measured from serum collected prior to and following the program. To understand the effect of fat mass loss on the serum levels of adipokine, which is mainly produced in adipose tissue, the leptin and adiponectin levels were also measured prior to and following the program. Serum leptin levels (mean ± standard error of the mean) decreased significantly following the program (from 9.82±0.98 to 7.23±0.67 ng/ml) and were closely correlated with body fat percentage. In addition, serum adiponectin levels were negatively correlated with body fat percentage, while serum adiponectin levels were not significantly altered. By contrast, serum OPN levels decreased significantly following the program (from 16.03±2.34 to 10.65±1.22 ng/ml). However, serum OPN levels were not correlated with body fat percentage, suggesting that serum OPN levels are controlled by several other factors in humans. In conclusion, a high expression of OPN in adipose tissues may not be correlated with serum OPN levels in obese humans. Thus, tissues or physiological factors other than fat mass may have a greater contribution to the serum OPN levels.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23764959     DOI: 10.3892/mmr.2013.1522

Source DB:  PubMed          Journal:  Mol Med Rep        ISSN: 1791-2997            Impact factor:   2.952


  9 in total

Review 1.  The obesity of bone.

Authors:  Emanuela A Greco; Andrea Lenzi; Silvia Migliaccio
Journal:  Ther Adv Endocrinol Metab       Date:  2015-12       Impact factor: 3.565

2.  Wogonin suppresses osteopontin expression in adipocytes by activating PPARα.

Authors:  Ye-min Zhang; Ming-xin Li; Zhao Tang; Chang-hua Wang
Journal:  Acta Pharmacol Sin       Date:  2015-06-15       Impact factor: 6.150

3.  Physical inactivity increases endostatin and osteopontin in patients with coronary artery disease.

Authors:  Michael Sponder; Monika Fritzer-Szekeres; Rodrig Marculescu; Brigitte Litschauer; Jeanette Strametz-Juranek
Journal:  Heart Vessels       Date:  2015-12-11       Impact factor: 2.037

Review 4.  Endocrine role of bone in the regulation of energy metabolism.

Authors:  Ruoyu Zhou; Qiaoyue Guo; Ye Xiao; Qi Guo; Yan Huang; Changjun Li; Xianghang Luo
Journal:  Bone Res       Date:  2021-05-20       Impact factor: 13.567

5.  In Vitro and In Vivo Effects of Metformin on Osteopontin Expression in Mice Adipose-Derived Multipotent Stromal Cells and Adipose Tissue.

Authors:  Agnieszka Śmieszek; Katarzyna Basińska; Klaudia Chrząstek; Krzysztof Marycz
Journal:  J Diabetes Res       Date:  2015-04-30       Impact factor: 4.011

6.  Leptin/Osteopontin Axis Regulated Type 2T Helper Cell Response in Allergic Rhinitis with Obesity.

Authors:  Qingxiang Zeng; Xi Luo; Miaomiao Han; Wenlong Liu; Huabin Li
Journal:  EBioMedicine       Date:  2018-06-07       Impact factor: 8.143

7.  Role of Leptin/Osteopontin Axis in the Function of Eosinophils in Allergic Rhinitis with Obesity.

Authors:  Wenlong Liu; Qingxiang Zeng; Yanqiu Chen; Ren Zhong Luo
Journal:  Mediators Inflamm       Date:  2018-10-24       Impact factor: 4.711

8.  Exercise training modulates the gut microbiota profile and impairs inflammatory signaling pathways in obese children.

Authors:  Rocío Quiroga; Esther Nistal; Brisamar Estébanez; David Porras; María Juárez-Fernández; Susana Martínez-Flórez; María Victoria García-Mediavilla; José A de Paz; Javier González-Gallego; Sonia Sánchez-Campos; María J Cuevas
Journal:  Exp Mol Med       Date:  2020-07-06       Impact factor: 8.718

Review 9.  Osteopontin: A novel regulator at the cross roads of inflammation, obesity and diabetes.

Authors:  Florian Kahles; Hannes M Findeisen; Dennis Bruemmer
Journal:  Mol Metab       Date:  2014-03-22       Impact factor: 7.422

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.